Primary Uterine Peripheral T-cell Lymphoma

A Case Report of MRI and $^{18}$F-FDG PET/CT Findings

Jing Gong, MD, Aisheng Dong, MD, Yang Wang, MSc, Xuefeng Zhang, MSc, Panpan Yang, BSc, Li Wang, MD, and Wei Jing, MD

INTRODUCTION

Uterine lymphoma can be primary or secondary with the later being more common. Approximately 24% of non-Hodgkin’s lymphomas are considered to be of extranodal origin. Primary uterine non-Hodgkin’s lymphomas are extremely rare accounting for <1% of all extranodal non-Hodgkin’s lymphomas.1,2 Early diagnosis and prompt treatment are essential for getting a better prognosis. However, the diagnosis of primary uterine lymphoma is often delayed due to its low incidence and nonspecific clinical presentation.2–4 The imaging findings of primary uterine lymphoma are rarely reported before.5–9 In this paper, we present magnetic resonance imaging (MRI) and fluorine-18-fluorodeoxyglucose ($^{18}$F-FDG) positron emission tomography (PET)/CT findings in a patient with primary uterine peripheral T-cell lymphoma.

CASE REPORT

A 27-year-old female was admitted to our hospital because of intermittent fever with neutropenia for 7 months. She gave birth to a healthy baby 7 months ago. On admission, a firm mass could be palpated at the lower abdomen. Laboratory tests showed decreased white blood cell count ($1.4 \times 10^9/L$; range $4–10 \times 10^9/L$). Serum cancer antigen 125 was elevated (193 U/mL; range $<35$ U/mL). Serum carcinoembryonic antigen, α-fetoprotein, and cancer antigen 19–9 were normal. Pelvic MRI was performed. MRI showed an ill-defined mass involved both the uterine corpus and cervix, resulting in diffuse enlargement of the uterus (stage, II E). After 3 circles of chemotherapy, follow-up enhanced MRI showed decreased thickness of the uterine wall (Figure 4).

The work cannot be used commercially.

Please note that the above text is a representation of the content in the image, and it adheres to the guidelines provided.
DISCUSSION

Primary uterine non-Hodgkin’s lymphomas are extremely rare accounting for <1% of all extranodal non-Hodgkin’s lymphomas.1,2 The mean age of patients with primary uterine non-Hodgkin’s lymphoma at presentation is 55 years and abnormal uterine bleeding is the most frequent complaint.3 Cervix is the most common site.3 Diffuse large B-cell lymphoma is the most common pathologic subtype.3 The combination of chemotherapy and irradiation is the most effective treatment regimen for uterine lymphomas.4

FIGURE 1. Transverse unenhanced T1-weighted image (A) showed an inhomogeneous hypointense mass (arrows) in the uterus. Corresponding transverse diffusion-weighted imaging (B) showed peripheral hypointensity of the mass. Sagittal T2-weighted MR image (C) showed the mass (arrows) involved both the endometrium and myometrium, resulting in diffuse enlargement of the uterus. This mass showed relative hypointensity compared to the surrounding myometrium. On transverse (D), coronal (E), and sagittal (F) enhanced T1-weighted images, this mass showed lower enhancement (arrows) than the surrounding myometrium. MR = magnetic resonance.

FIGURE 2. Maximum intensity projection PET (A) showed intense FDG uptake of the enlarged uterus (arrow) and multiple hypermetabolic lymph nodes (arrowheads) in the pelvis and retroperitoneum. Transverse CT (B, C), corresponding PET (D, E), and fused (F, G) images showed intense FDG uptake in the thickened wall of the uterine corpus (arrows) and cervix (arrowhead) with SUVmax of 26.9. CT = computed tomography, FDG = fluorodeoxyglucose, MRI = magnetic resonance imaging, PET = positron emission tomography.
On MRI, diffuse enlargement of the uterus, relatively homogeneous signal intensity, and multinodular growth pattern are helpful for diagnosing uterine lymphoma.\(^5,6\) In this case, on T2-weighted MR images, the tumor showed relative hypointensity compared to the surrounding myometrium, which may be due to the hypercellularity and less necrosis of the tumor. On diffusion-weighted imaging, the tumor showed remarkable hyperintensity indicating marked restricted diffusion of the water molecules due to the dense microstructure. On enhanced T1-weighted MR images, the tumor showed lower enhancement than the surrounding myometrium, which may be due to the minimal tumor angiogenesis and destroying of the normal uterine vessels. MRI may be helpful for the differential diagnosis between uterine lymphoma and uterine leiomyosarcoma or abscess. Unlike uterine lymphoma, hemorrhage and necrosis are common in uterine leiomyosarcoma. Therefore, uterine leiomyosarcoma commonly manifests as a large infiltrating myometrial mass with heterogeneous hypointensity on T1-weighted MR images, and intermediate-to-high signal intensity with central hyperintensity on T2-weighted MR images.\(^7\) Uterine abscesses commonly show high-signal intensity on T2-weighted MR images, which is different from relative hypointensity of uterine lymphoma.

Information on FDG PET/CT findings of uterine lymphoma is limited. FDG PET/CT may be useful for detection, staging, and treatment evaluation of uterine lymphoma.\(^2,8,9\) High-grade uterine lymphomas usually show intense FDG uptake,\(^2,8,9\) whereas the low-grade ones show lower FDG uptake.\(^10\) Therefore, FDG PET/CT may be helpful for assessment of the tumor grade. This case indicates uterine lymphoma should be included in the differential diagnosis of abnormal uterine FDG accumulation along with physiological endometrial uptake,\(^11\) postpartum uterus,\(^12\) adenomyosis,\(^13,14\) endometrial hyperplasia,\(^13,14\) leiomyoma,\(^14,15,16\) cervical cancer,\(^14,17\) endometrial cancer,\(^14,18\) choriocarcinoma,\(^19\) uterine sarcoma,\(^14,16,20\) and uterine metastasis.\(^14,21\)

In conclusion, primary uterine non-Hodgkin’s lymphoma should be taken into consideration when a uterine tumor shows large size, relative hypointensity on both T2-weighted images and enhanced T1-weighted images compared to the surrounding myometrium, and intense FDG uptake on PET/CT. MRI may be helpful for describing the relationship between the tumor and adjacent structures. FDG PET/CT may be useful for tumor detection and staging.

ETHICAL REVIEW AND CONSENT

Ethical approval was obtained from the Ethics Committee of Shanghai Hospital, Shanghai, China. Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

REFERENCES

1. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29:252–260.
2. Frey NV, Svoboda J, Andreidis C, et al. Primary lymphomas of the cervix and uterus: the University of Pennsylvania’s experience and a review of the literature. Leuk Lymphoma. 2006;47:1894–1901.
3. Vang R, Medeiros LJ, Ha CS, et al. Non-Hodgkin’s lymphomas involving the uterus: a clinicopathologic analysis of 26 cases. Mod Pathol. 2000;13:19–28.
4. Stroh EL, Besa PC, Cox JD, et al. Treatment of patients with lymphomas of the uterus or cervix with combination chemotherapy and radiation therapy. Cancer. 1995;75:2392–2399.
5. Kim YS, Koh BH, Cho OK, et al. MR imaging of primary uterine lymphoma. Abdom Imaging. 1997;22:441–444.
6. Goto N, Oishi-Tanaka Y, Tsunoda H, et al. Magnetic resonance findings of primary uterine malignant lymphoma. Magn Reson Med Sci. 2007;6:7–13.
7. Santos P, Cunha TM. Uterine sarcomas: clinical presentation and MRI features. Diagn Interv Radiol. 2015;21:4–9.

8. Bural GG, Shriaknthen S, Houseni M, et al. FDG-PET is useful in staging and follow-up of primary uterine cervical lymphoma. Clin Nucl Med. 2007;32:748–750.

9. Lannoo L, Smets S, Steenkiste E, et al. Intravascular large B-cell lymphoma of the uterus presenting as fever of unknown origin (FUO) and revealed by FDG-PET. Acta Clin Belg. 2007;62:187–190.

10. Alinari L, Castellucci P, Elstrom R, et al. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma. 2006;47:2096–2101.

11. Nishizawa S, Imbuschi M, Okada H. Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging. 2005;32:549–556.

12. Lin E. FDG PET appearance of a postpartum uterus. Clin Nucl Med. 2006;31:159–160.

13. Yu JI, Huh SJ, Kim YI, et al. Variable uterine uptake of FDG in adenomyosis during concurrent chemoradiation therapy for cervical cancer. Radiat Oncol J. 2011;29:214–217.

14. Kitajima K, Murakami K, Kaji Y, et al. Spectrum of FDG PET/CT findings of uterine tumors. AJR Am J Roentgenol. 2010;195:737–743.

15. Jehanno N, Wartski M, Malhaire C, et al. 18F-FDG PET/CT findings in uterine leiomyomas. Eur J Nucl Med Mol Imaging. 2014;41:1034–1035.

16. Zhao Z, Yoshida Y, Kurokawa T, et al. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis. J Nucl Med. 2013;54:499–506.

17. Kidd EA, Spencer CR, Huettner PC, et al. Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer. 2009;115:3548–3554.

18. Lee SI, Catalano OA, Dehdashti F. Evaluation of gynecologic cancer with MR imaging, 18F-FDG PET/CT, and PET/MR imaging. J Nucl Med. 2015;56:436–443.

19. Dose J, Bohuslavizki K, Häneke B, et al. Detection of intramural choriocarcinoma of the uterus with 18F-FDG-PET: a case report. Clin Positron Imaging. 2000;3:37–40.

20. Dong A, Zuo C, Wang Y, et al. Enhanced CT and FDG PET/CT in primary malignant peripheral nerve sheath tumor of the uterine cervix. Clin Nucl Med. 2014;39:825–827.

21. Muñoz-Iglesias J, Uña-Gorospe J, Allende-Riera A, et al. Unsuspected uterine metastasis of breast carcinoma diagnosed by 18F-FDG PET/CT. Clin Nucl Med. 2013;38:e441–e442.